Literature DB >> 6135635

A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 2. Marked attenuation of the metabolic deterioration by somatostatin.

A J Scheen, G Krzentowski, M Castillo, P J Lefèbvre, A S Luyckx.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6135635     DOI： 10.1007/bf00251816

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  22 in total

Review 1.  Somatostatin: physiological and clinical significance.

Authors:  R Guillemin; J E Gerich
Journal:  Annu Rev Med       Date:  1976       Impact factor: 13.739

2.  Specific inhibition by somatostatin of growth hormone release after hypoglycaemia in normal man.

Authors:  G Copinschi; E Virasoro; L Vanhaelst; R Leclercq; J Golstein; M L'Hermite
Journal:  Clin Endocrinol (Oxf)       Date:  1974-10       Impact factor: 3.478

3.  Inhibition of the sleep-related peak in physiologic human growth hormone release by somatostatin.

Authors:  D C Parker; L G Rossman; T M Siler; J Rivier; S S Yen; R Guillemin
Journal:  J Clin Endocrinol Metab       Date:  1974-03       Impact factor: 5.958

Review 4.  Regulation of hepatic fatty acid oxidation and ketone body production.

Authors:  J D McGarry; D W Foster
Journal:  Annu Rev Biochem       Date:  1980       Impact factor: 23.643

5.  Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon.

Authors:  J E Gerich; M Lorenzi; D M Bier; V Schneider; E Tsalikian; J H Karam; P H Forsham
Journal:  N Engl J Med       Date:  1975-05-08       Impact factor: 91.245

6.  Effect of somatostatin on metabolic and hormonal changes induced by nicotinic acid in insulin-dependent diabetics.

Authors:  A S Luyckx; P J Lefebvre
Journal:  Diabetologia       Date:  1976-10       Impact factor: 10.122

7.  Evidence for an important role of glucagon in the regulation of hepatic glucose production in normal man.

Authors:  J E Liljenquist; G L Mueller; A D Cherrington; U Keller; J M Perry; W W Lacy; D Rabinowitz
Journal:  J Clin Invest       Date:  1977-02       Impact factor: 14.808

8.  Ketoacidosis in pancreatectomized man.

Authors:  A J Barnes; S R Bloom; K Goerge; G M Alberti; P Smythe; F P Alford; D J Chisholm
Journal:  N Engl J Med       Date:  1977-06-02       Impact factor: 91.245

9.  Insulin, glucagon, and somatostatin in normal physiology and diabetes mellitus.

Authors:  P Felig; J Wahren; R Sherwin; R Hendler
Journal:  Diabetes       Date:  1976-12       Impact factor: 9.461

10.  Influence of somatostatin on carbohydrate disposal and absorption in diabetes mellitus.

Authors:  J Wahren
Journal:  Lancet       Date:  1976-12-04       Impact factor: 79.321
View more
  2 in total

1.  Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients.

Authors:  A J Scheen; J Gillet; J Rosenthaler; J Guiot; P Henrivaux; B Jandrain; P J Lefèbvre
Journal:  Diabetologia       Date:  1989-11       Impact factor: 10.122

2.  Prevention of nocturnal hypoglycemia using predictive alarm algorithms and insulin pump suspension.

Authors:  Bruce Buckingham; H Peter Chase; Eyal Dassau; Erin Cobry; Paula Clinton; Victoria Gage; Kimberly Caswell; John Wilkinson; Fraser Cameron; Hyunjin Lee; B Wayne Bequette; Francis J Doyle
Journal:  Diabetes Care       Date:  2010-03-03       Impact factor: 19.112
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.